Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biophilus
- Development stage
- Unknown
- Lead developer
- Biose Industrie
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Biophilus (also marketed as Antibiophilus) is a probiotic preparation containing the live lactic acid bacterium *Lactobacillus rhamnosus* (specifically the *Lactobacillus rhamnosus* LCR35 strain, formerly classified as *Lactobacillus casei variety rhamnosus*). Developed originally by Laboratoires Lyocentre and marketed by companies including Orion Pharma and Germania Pharmazeutika, it is used to restore and maintain a balanced intestinal microbiota. It is primarily indicated for the prevention and treatment of diarrhea of various origins, including antibiotic-associated diarrhea and radiation-induced diarrhea, as well as other gastrointestinal disorders like irritable bowel syndrome (IBS) and constipation. The probiotic works by colonizing the gastrointestinal tract, competing with pathogenic microorganisms, producing lactic acid and other bacteriostatic metabolites, and modulating the mucosal immune response.
- Brand names
- AntibiophilusBiophilus
- Other names
- LCR 35LCR35LCR-35Lactobacillus casei rhamnosusLactobacillus casei variety rhamnosusLactobacillus rhamnosusLactobacillus rhamnosus LCR35
Beyond the preview
Go deeper on Biophilus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biophilus.